The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.
Midostaurin: a magic bullet that blocks mast cell expansion and activation
Open accessAbstract
Clinically relevant features in patients with systemic mastocytosis (SM) include the cosmetic burden of lesional skin, mediator-related symptoms, and organ damage resulting from mast cell (MC) infiltration in advanced forms of SM. Regardless of the SM variant, expansion of neoplastic MC in the skin and other organs is triggered by mutant forms of KIT, the most prevalent being D816V. Activation of MC with subsequent release of chemical mediators is often caused by IgE-dependent mechanisms in these patients. Midostaurin, also known as PKC412, blocks the kinase activity of wild-type KIT and KIT D816V, counteracts KIT-dependent growth of neoplastic MC, and inhibits IgE-dependent mediator secretion. Based on this activity-profile, the drug has been used for treatment of patients with advanced SM. Indeed, encouraging results have been obtained with the drug in a recent multi-center phase II trial in patients with advanced SM, with an overall response rate of 60% and a substantial decrease in the burden of neoplastic MC in various organs. Moreover, midostaurin improved the overall survival and relapse-free survival in patients with advanced SM compared with historical controls. In addition, midostaurin was found to improve mediator-related symptoms and quality of life, suggesting that the drug may also be useful in patients with indolent SM suffering from mediator-related symptoms resistant to conventional therapies or those with MC activation syndromes. Ongoing and future studies will determine the actual value of midostaurin-induced MC depletion and MC deactivation in these additional indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, midostaurin is a broadly acting signal transduction inhibitor that recognizes kinase targets (such as SYK) downstream of the IgE receptor.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · cited 2×
“Molecular targets were identified in a cell-free screen [42] and in a chemical proteomics approach using primary neoplastic mast cells [43].”
BackgroundStaurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452 · cited 1×
“Midostaurin, originally termed PKC412, is a semi-synthetic derivative of the alkaloid staurosporine, a well-known inhibitor of PKC (Figure 1A) [41].”
BackgroundBorst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., & Kanayama, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116761 · Cited by 816
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“For those who are not eligible for SCT or refuse this therapy, investigational drugs are usually recommended [5, 9, 10, 22, 23].”
BackgroundSelf-citationLongley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H., & Modlin, I. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 607
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Lim, K.-H., Tefferi, A., Lasho, T. L., Finke, C., Patnaik, M., Butterfield, J. H., McClure, R. F., Li, C.-Y., & Pardanani, A. (2009) · Blood · doi:10.1182/blood-2009-02-205237 · Cited by 588
Brockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Research works printed but not linked: 1
- Van Anrooij, 2016, Midostaurin (PKC412) in indolent systemic mastocytosis: a phase 2 trial, EHA Learning Center
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Self-citationUnderstanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Self-citationNew Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
Valent, P., Akin, C., Sperr, W. R., Horny, H., Arock, M., Metcalfe, D. D., & Galli, S. J. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-042618 · Cited by 108
Self-citation
Metadata
- Authors
- Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., Hermine, O., Kluin-Nelemans, H. C., Arock, M., Horny, H.-P., Reiter, A., & Gotlib, J.
- Affiliations
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- University of Michigan (US)
- University of Lübeck (DE)
- University of New Mexico (US)
- Paracelsus Medical University (AT)
- Novartis (Switzerland) (CH)
- Sorbonne Paris Cité (FR)
- Centre National de la Recherche Scientifique (FR)
- Pathologisches Institut (DE)
- Heidelberg University (DE)
- Stanford Cancer Institute (US)
- Corresponding author
- Valent, P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 28
- Issue
- 10
- Pages
- 2367-2376
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC7115852
- OpenAlex
- W2753355630
- Cited by
- 79
- References
- 79
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 13 · 2022: 8 · 2021: 14 · 2020: 11 · 2019: 15 · 2018: 5
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 793 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- edoc (University of Basel) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Austrian Science Fund (F4704-B20)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- midostaurin, systemic mastocytosis, KIT D816V mutation, mast cell activation, tyrosine kinase inhibitors, mast cell degranulation, mast cell activation syndrome, indolent systemic mastocytosis, survival outcomes
- MeSH terms
- Antineoplastic Agents, Humans, Mast Cells, Multicenter Studies as Topic, Clinical Trials, Phase II as Topic, Drug Resistance, Neoplasm, Staurosporine, Mastocytosis, Systemic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Midostaurin: a magic bullet that blocks mast cell expansion and activation. https://app.cochat.ai/papers/10.1093/annonc/mdx290
- The paper
- Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., Hermine, O., Kluin-Nelemans, H. C., Arock, M., Horny, H.-P., Reiter, A., & Gotlib, J. (2017). Midostaurin: a magic bullet that blocks mast cell expansion and activation. Annals of Oncology. https://doi.org/10.1093/annonc/mdx290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.